Filing Details
NOVAVAX INC (NASDAQ:NVAX) filed its quarterly report (Form 10-Q) with the Securities and Exchange Commission on November 05, 2026.
The Healthcare company reported Q0 revenue of .
10q filedNASDAQ:NVAX
NOVAVAX INC (NVAX) Files Quarterly Report for Q0
NOVAVAX INC (NASDAQ:NVAX) filed its quarterly report (Form 10-Q) with the Securities and Exchange Commission on November 05, 2026.
At publication ·
What changed
NOVAVAX INC (NASDAQ:NVAX) · 10q filed
- Form
- 10-Q
At a glance
Key takeaways
- Novavax filed its quarterly report (Form 10-Q) with the SEC on November 5, 2026.
- The company's stock trades at $10.65 with a market capitalization of $1.1 billion.
- The 10-Q filing contains unaudited financial statements and management commentary on recent business performance and conditions.
Market Context
NOVAVAX INC's stock currently trades at $10.65 with a market capitalization of $1.1B.
The 10-Q provides NOVAVAX INC's quarterly financial update, including unaudited financial statements and management commentary on recent performance. While less detailed than the annual 10-K, the 10-Q often contains timely information about emerging trends, updated risk factors, and changes in business conditions since the last filing.
All SEC filings for NOVAVAX INC are publicly available through the SEC's EDGAR database. Investors can set up alerts for new filings to stay current on material developments.
Related Tools: View NVAX Stock Page
Frequently Asked Questions
Where can I read NVAX's SEC filings?
Browse all filings on our NVAX SEC filings page.
What types of SEC filings does NOVAVAX INC file?
Public companies like NOVAVAX INC file annual reports (10-K), quarterly reports (10-Q), material events (8-K), and insider transactions (Form 4) with the SEC.